114 related articles for article (PubMed ID: 37343421)
1. CD8 + T-cell number and function are altered by Shkbp1 knockout mediated suppression of tumor growth in mice.
Guo X; Li H; Meng X; Zhao Z; Zhang R; Wang L; Li J
Mol Immunol; 2023 Aug; 160():32-43. PubMed ID: 37343421
[TBL] [Abstract][Full Text] [Related]
2. Suppression of tumor growth and metastasis in Shkbp1 knockout mice.
Liu Q; Li H; Yang M; Mei Y; Niu T; Zhou Z; Zhang X; He X; Wang L; Li J
Cancer Gene Ther; 2022 Jun; 29(6):709-721. PubMed ID: 34112919
[TBL] [Abstract][Full Text] [Related]
3. Dok-1 and Dok-2 Regulate the Formation of Memory CD8+ T Cells.
Laroche-Lefebvre C; Yousefi M; Daudelin JF; Charpentier T; Tarrab E; Klinck R; Lamarre A; Labrecque N; Stäger S; Duplay P
J Immunol; 2016 Nov; 197(9):3618-3627. PubMed ID: 27664281
[TBL] [Abstract][Full Text] [Related]
4. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
5. Reinforcement of cancer immunotherapy by adoptive transfer of cblb-deficient CD8+ T cells combined with a DC vaccine.
Lutz-Nicoladoni C; Wallner S; Stoitzner P; Pircher M; Gruber T; Wolf AM; Gastl G; Penninger JM; Baier G; Wolf D
Immunol Cell Biol; 2012 Jan; 90(1):130-4. PubMed ID: 21383769
[TBL] [Abstract][Full Text] [Related]
6. Signal-transducing adaptor protein-2 promotes generation of functional long-term memory CD8+ T cells by preventing terminal effector differentiation.
Muraoka D; Seo N; Hayashi T; Hyuga-Amaike C; Okamori K; Tawara I; Harada N; Shiku H
Oncotarget; 2017 May; 8(19):30766-30780. PubMed ID: 28430604
[TBL] [Abstract][Full Text] [Related]
7. Lack of Sprouty 1 and 2 enhances survival of effector CD8
Shehata HM; Khan S; Chen E; Fields PE; Flavell RA; Sanjabi S
Proc Natl Acad Sci U S A; 2018 Sep; 115(38):E8939-E8947. PubMed ID: 30126987
[TBL] [Abstract][Full Text] [Related]
8. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
9. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.
Avogadri F; Merghoub T; Maughan MF; Hirschhorn-Cymerman D; Morris J; Ritter E; Olmsted R; Houghton AN; Wolchok JD
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844763
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity.
Berezhnoy A; Castro I; Levay A; Malek TR; Gilboa E
J Clin Invest; 2014 Jan; 124(1):188-97. PubMed ID: 24292708
[TBL] [Abstract][Full Text] [Related]
11. COPS6 promotes tumor progression and reduces CD8
Du WQ; Zhu ZM; Jiang X; Kang MJ; Pei DS
Acta Pharmacol Sin; 2023 Sep; 44(9):1890-1905. PubMed ID: 37095198
[TBL] [Abstract][Full Text] [Related]
12. Accumulation of cytolytic CD8+ T cells in B16-melanoma and proliferation of mature T cells in TIS21-knockout mice after T cell receptor stimulation.
Ryu MS; Woo MY; Kwon D; Hong AE; Song KY; Park S; Lim IK
Exp Cell Res; 2014 Oct; 327(2):209-21. PubMed ID: 25088256
[TBL] [Abstract][Full Text] [Related]
13. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.
Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD
Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.
Oda SK; Strauch P; Fujiwara Y; Al-Shami A; Oravecz T; Tigyi G; Pelanda R; Torres RM
Cancer Immunol Res; 2013 Oct; 1(4):245-55. PubMed ID: 24455753
[TBL] [Abstract][Full Text] [Related]
15. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
Thompson ED; Enriquez HL; Fu YX; Engelhard VH
J Exp Med; 2010 Aug; 207(8):1791-804. PubMed ID: 20660615
[TBL] [Abstract][Full Text] [Related]
16. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
17. Topical treatment of all-trans retinoic acid inhibits murine melanoma partly by promoting CD8
Yin W; Song Y; Liu Q; Wu Y; He R
Immunology; 2017 Oct; 152(2):287-297. PubMed ID: 28556970
[TBL] [Abstract][Full Text] [Related]
18. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens.
Côté AL; Zhang P; O'Sullivan JA; Jacobs VL; Clemis CR; Sakaguchi S; Guevara-Patiño JA; Turk MJ
J Immunol; 2011 Jan; 186(1):275-83. PubMed ID: 21106849
[TBL] [Abstract][Full Text] [Related]
20. SH3KBP1-binding protein 1 prevents epidermal growth factor receptor degradation by the interruption of c-Cbl-CIN85 complex.
Feng L; Wang JT; Jin H; Qian K; Geng JG
Cell Biochem Funct; 2011 Oct; 29(7):589-96. PubMed ID: 21830225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
